Schneeweiss, A., Park-Simon, T., Albanell, J., Lassen, U., Cortés, J., , … Cervantes, A. (2018). Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer. Investigational New Drugs. https://doi.org/10.1007/s10637-018-0562-4 (Original work published 2018)